Bausch Health Companies 과거 수익 실적

과거 기준 확인 0/6

Bausch Health Companies은 연평균 34.6%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 2.1%의 비율로 수입이 증가했습니다. 매출은 연평균 1.6%의 비율로 증가했습니다.

주요 정보

34.6%

수익 성장률

35.4%

EPS 성장률

Pharmaceuticals 산업 성장	6.0%
매출 성장률	1.6%
자기자본 수익률	n/a
순이익	-1.9%
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

Recent updates

There's No Escaping Bausch Health Companies Inc.'s (NYSE:BHC) Muted Revenues Despite A 28% Share Price Rise

Oct 10

Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely

Sep 19

Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%

Aug 06

2 Red Alerts On Bausch Health Companies

Jul 25

The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

May 21

Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues

Nov 10

Bausch Health Companies Q3 2022 Earnings Preview

Nov 02

Bausch Health: Long-Term Need To Place Stops For Protection

Sep 28

수익 및 비용 분석

Bausch Health Companies 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NYSE:BHC 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 24	9,474	-178	3,229	605
30 Jun 24	9,202	-471	3,090	612
31 Mar 24	8,966	-455	2,965	612
31 Dec 23	8,757	-592	2,895	604
30 Sep 23	8,542	-963	2,789	594
30 Jun 23	8,350	-186	2,720	574
31 Mar 23	8,150	-357	2,652	545
31 Dec 22	8,124	-225	2,531	529
30 Sep 22	8,127	254	2,514	504
30 Jun 22	8,192	43	2,490	492
31 Mar 22	8,325	-407	2,504	480
31 Dec 21	8,434	-948	2,492	465
30 Sep 21	8,451	-1,170	2,472	467
30 Jun 21	8,478	-1,287	2,423	449
31 Mar 21	8,042	-1,018	2,299	442
31 Dec 20	8,027	-560	2,367	452
30 Sep 20	8,038	-1,923	2,395	447
30 Jun 20	8,109	-2,043	2,475	467
31 Mar 20	8,597	-1,888	2,600	476
31 Dec 19	8,601	-1,788	2,554	471
30 Sep 19	8,498	-616	2,512	477
30 Jun 19	8,425	-917	2,478	461
31 Mar 19	8,401	-1,619	2,469	438
31 Dec 18	8,380	-4,148	2,473	413
30 Sep 18	8,422	-3,291	2,486	383
30 Jun 18	8,505	-1,640	2,495	357
31 Mar 18	8,610	-805	2,512	357
31 Dec 17	8,724	2,404	2,582	361
30 Sep 17	8,964	1,376	2,609	364
30 Jun 17	9,224	-1,143	2,645	384
31 Mar 17	9,411	-1,407	2,657	414
31 Dec 16	9,674	-2,409	2,782	421
30 Sep 16	10,024	-2,280	2,826	424
30 Jun 16	10,332	-1,013	2,865	424
31 Mar 16	10,644	-764	2,879	381
31 Dec 15	10,442	-292	2,700	334
30 Sep 15	9,906	596	2,481	298
30 Jun 15	9,175	822	2,288	255
31 Mar 15	8,484	1,001	2,118	241
31 Dec 14	8,200	881	2,026	246
30 Sep 14	8,043	502	1,952	246
30 Jun 14	7,529	-746	1,804	236
31 Mar 14	6,583	-861	1,545	194
31 Dec 13	5,766	-866	1,305	157

양질의 수익: BHC 은(는) 현재 수익성이 없습니다.

이익 마진 증가: BHC 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: BHC 은(는) 수익성이 없지만 지난 5년 동안 연간 34.6% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 BHC 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: BHC 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 54.6% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: BHC 의 부채가 자산을 초과하므로 자기자본수익률을 계산하기 어렵습니다.

Bausch Health Companies 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024

First quarter 2024 earnings: EPS misses analyst expectations

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Recent updates

Price target increased by 7.1% to US$8.57

Forecast breakeven date pushed back to 2025

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA

There's No Escaping Bausch Health Companies Inc.'s (NYSE:BHC) Muted Revenues Despite A 28% Share Price Rise

Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024

Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely

Price target decreased by 18% to US$7.79

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Executive VP & General Counsel exercised options and sold US$318k worth of stock

Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%

Price target decreased by 11% to US$8.36

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024

2 Red Alerts On Bausch Health Companies

Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma

Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024

Price target decreased by 7.7% to US$9.56

The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Bausch Health Companies Inc. Approves Directorate Appointments

Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results

First quarter 2024 earnings: EPS misses analyst expectations

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Price target increased by 10% to US$10.33

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall from profit to US$0.03 loss

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel

Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis

Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan

Bausch Health: $20bn Debt Is A Mighty Elephant In The Room

Consensus EPS estimates fall by 89%, revenue upgraded

New major risk - Negative shareholders equity

No longer forecast to breakeven

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

Consensus EPS estimates fall by 31%

Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023

Consensus EPS estimates fall from profit to US$0.49 loss

Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics

Price target increased by 11% to US$9.50

Bausch Health Companies Inc. Announces Executive Changes

Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Executive VP & CFO exercised options to buy US$1.1m worth of stock.

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Consensus EPS estimates increase from loss to US$0.11 profit

Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022)

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc

Is Bausch Health Companies (NYSE:BHC) A Risky Investment?

Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023

Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes

New major risk - Financial position

Consensus EPS estimates fall by 299%

Price target decreased by 29% to US$8.50

What To Do After Bausch Health Stock Plunged By Nearly 9% Again

Consensus EPS estimates upgraded to US$0.18 loss

Price target decreased by 8.9% to US$11.92

Consensus EPS estimates upgraded to US$0.33 loss